Men's health has a measurement problem, and genomics is positioned to solve it. For decades, the conversation about male genomic risk has centered almost entirely on prostate cancer, while a far wider landscape of actionable markers has gone largely unexamined. For clinicians and diagnostic leads, this represents both a clinical gap and a medical affairs opportunity. This article reframes men's health genomics beyond the prostate, surveying cardiovascular, pharmacogenomic, hereditary cancer, fertility, and digital biomarker evidence that should inform contemporary male health screening.
The data on male engagement is sobering. In 2022, the U.S. life expectancy was 74.8 years for men and 80.2 years for women, a gap that has widened over the last decade. According to the CDC, men are 50% less likely than women to seek medical attention. And the federal policy just reflects the neglect – the Healthy People 2030 framework includes just four goals targeting men, fewer than for any other group.
This avoidance extends directly into genomics. While 73% of women reported receiving genetic testing, only 27% of men did. This is a disparity driven largely by hereditary breast and ovarian cancer testing protocols designed around women. Even in 2026, testing for hereditary cancer genes in men continues to be a missed opportunity for cancer prevention. Only 5% of men were tested for hereditary cancer genes, yet showed a pathogenic variant positivity rate of 14% versus 8% in women. The signal is clear: when men are tested, they test positive more often. Genomic markers for men's health are missing at scale.
Let's look at the most common diseases in males, their leading causes, and the research conducted so far.
Cardiovascular disease is the leading cause of male mortality, and polygenic risk scoring is changing how that risk is identified. Research presented at the American Heart Association in 2025 found that adding polygenic risk scores to the PREVENT tool improved cardiovascular risk prediction across ancestries, and that over 3 million people aged 40–70 in the US are at high risk but invisible to current screening because genetics is not used in standard risk calculators. One analysis found the number of men needed to screen to prevent one cardiovascular event fell from 149 to 116 when polygenic risk scores were added to primary-care prioritization. These are exactly the male health biomarkers that extend genomic value beyond oncology.
Pharmacogenomics offers some of the most immediate actionable insights. The CYP2C19 gene determines how patients metabolize clopidogrel, a common antiplatelet drug, and reduced-function alleles are associated with a higher risk of stent thrombosis, myocardial infarction, and death. A 2025 study found a 38% excess incidence of adverse events among metabolizers who received inappropriate prescriptions in the absence of pharmacogenomic testing. For a male population already prone to cardiovascular disease and late presentation, pharmacogenomic screening is a high-yield intervention.
Hereditary cancer panels capture risk that prostate-centric thinking ignores. Studies found that population-based germline testing for Lynch syndrome could identify up to 63.2% of carriers who might remain undetected due to a lack of personal or family cancer history . Men with Lynch syndrome face elevated colorectal, gastric, and other cancer risks, yet referral remains low.
Reproductive genomics is a frequently overlooked dimension of male health. The 2024 AUA/ASRM guideline recommends Y-chromosome microdeletion analysis for men with azoospermia or sperm concentration at or below 1 million sperm/mL accompanied by elevated FSH, testicular atrophy, or impaired sperm production. Y-chromosome microdeletions are the second most common genetic cause of male infertility, and CFTR mutation testing is indicated for men with vasal agenesis or obstructive azoospermia. These tests carry implications well beyond conception, informing broader metabolic and oncologic risk.
The diagnostic frontier is increasingly digital. Over 70% of healthcare organizations now actively use AI, up from 63% in 2025, with usage of generative AI and large language models rising from 54% to 69%. In pharma and biotech, nearly half of respondents cited drug discovery and biomarker identification as leading use cases. In parallel, wearable devices integrating photoplethysmography, ECG, and machine learning now enable early detection of arrhythmias, hypertension, and ischemic events. Combined with genomic risk, these digital biomarkers create continuous, personalized monitoring well suited to men who avoid clinics.
If you’ve been wondering what genomic tests help men's health? Multi-gene panels covering BRCA1/2, mismatch repair genes, and Lynch-associated variants simultaneously identify risks for male breast, pancreatic, colorectal, and aggressive prostate cancers.
Adoption is accelerating on two fronts: a burgeoning men's health genomics market in both India and the US, and rapid penetration into Tier II and III cities. Meanwhile, genomic screening for men in US clinics is supported by initiatives such as the All of Us Research Program and growing payer recognition of polygenic and pharmacogenomic testing. ClairLabs works at this intersection, applying AI and data science to make male genomic risk legible to clinicians.
Prostate cancer is the beginning of the male genomic story, not the end. From cardiovascular polygenic risk to pharmacogenomics, hereditary cancer panels, fertility markers, and digital biomarkers, the tools to close the men's health gap already exist. The clinical mandate is to deploy them.